TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis
USA - NASDAQ:TMDX - US89377M1099 - Common Stock
116.7 USD
-2.48 (-2.08%)
TMDX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. TMDX has an excellent financial health rating, but there are some minor concerns on its profitability. TMDX is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make TMDX suitable for growth investing!
1. Profitability
1.1 Basic Checks
TMDX had positive earnings in the past year.
TMDX had a positive operating cash flow in the past year.
In the past 5 years TMDX reported 4 times negative net income.
TMDX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
TMDX has a better Return On Assets (9.70%) than 92.59% of its industry peers.
TMDX has a better Return On Equity (25.83%) than 95.77% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.75%, TMDX belongs to the top of the industry, outperforming 87.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.83% | ||
| ROIC | 8.75% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 16.20%, TMDX belongs to the top of the industry, outperforming 92.06% of the companies in the same industry.
TMDX has a better Operating Margin (16.94%) than 86.77% of its industry peers.
Looking at the Gross Margin, with a value of 60.28%, TMDX is in the better half of the industry, outperforming 60.85% of the companies in the same industry.
TMDX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
TMDX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
TMDX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TMDX has more shares outstanding
Compared to 1 year ago, TMDX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.17 indicates that TMDX is not in any danger for bankruptcy at the moment.
TMDX's Altman-Z score of 5.17 is fine compared to the rest of the industry. TMDX outperforms 77.78% of its industry peers.
TMDX has a debt to FCF ratio of 4.24. This is a neutral value as TMDX would need 4.24 years to pay back of all of its debts.
TMDX's Debt to FCF ratio of 4.24 is amongst the best of the industry. TMDX outperforms 80.42% of its industry peers.
TMDX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
TMDX has a Debt to Equity ratio of 1.43. This is amonst the worse of the industry: TMDX underperforms 80.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Altman-Z | 5.17 |
ROIC/WACC1.1
WACC7.99%
2.3 Liquidity
TMDX has a Current Ratio of 7.69. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.69, TMDX belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
TMDX has a Quick Ratio of 7.13. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.13, TMDX belongs to the top of the industry, outperforming 90.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 162.77% over the past year.
TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.20%.
Measured over the past years, TMDX shows a very strong growth in Revenue. The Revenue has been growing by 79.64% on average per year.
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
Based on estimates for the next years, TMDX will show a very strong growth in Earnings Per Share. The EPS will grow by 44.52% on average per year.
TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.23% yearly.
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 47.25, TMDX can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 67.72% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of TMDX to the average of the S&P500 Index (26.34), we can say TMDX is valued expensively.
Based on the Price/Forward Earnings ratio of 39.99, the valuation of TMDX can be described as expensive.
Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than 70.90% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of TMDX to the average of the S&P500 Index (34.43), we can say TMDX is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.25 | ||
| Fwd PE | 39.99 |
4.2 Price Multiples
70.37% of the companies in the same industry are more expensive than TMDX, based on the Enterprise Value to EBITDA ratio.
77.25% of the companies in the same industry are more expensive than TMDX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 32.97 | ||
| EV/EBITDA | 33.86 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TMDX's earnings are expected to grow with 53.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y69.97%
EPS Next 3Y53.74%
5. Dividend
5.1 Amount
TMDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:TMDX (11/13/2025, 12:25:08 PM)
116.7
-2.48 (-2.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.43%
Inst Owner Change-0.77%
Ins Owners2.96%
Ins Owner Change2.28%
Market Cap3.98B
Revenue(TTM)566.35M
Net Income(TTM)91.77M
Analysts83.16
Price Target149.33 (27.96%)
Short Float %24.1%
Short Ratio8.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)-0.07%
PT rev (3m)-3.05%
EPS NQ rev (1m)-6.26%
EPS NQ rev (3m)-9.04%
EPS NY rev (1m)9.57%
EPS NY rev (3m)43.63%
Revenue NQ rev (1m)0.42%
Revenue NQ rev (3m)2.28%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)3.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.25 | ||
| Fwd PE | 39.99 | ||
| P/S | 7.02 | ||
| P/FCF | 32.97 | ||
| P/OCF | 22.35 | ||
| P/B | 11.2 | ||
| P/tB | 11.64 | ||
| EV/EBITDA | 33.86 |
EPS(TTM)2.47
EY2.12%
EPS(NY)2.92
Fwd EY2.5%
FCF(TTM)3.54
FCFY3.03%
OCF(TTM)5.22
OCFY4.47%
SpS16.61
BVpS10.42
TBVpS10.02
PEG (NY)0.29
PEG (5Y)N/A
Graham Number24.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.83% | ||
| ROCE | 11.08% | ||
| ROIC | 8.75% | ||
| ROICexc | 18.94% | ||
| ROICexgc | 19.61% | ||
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% | ||
| FCFM | 21.3% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Debt/EBITDA | 4.18 | ||
| Cap/Depr | 225.79% | ||
| Cap/Sales | 10.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.67% | ||
| Profit Quality | 131.47% | ||
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 | ||
| Altman-Z | 5.17 |
F-Score7
WACC7.99%
ROIC/WACC1.1
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
EBIT growth 1Y205.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year292.7%
EBIT Next 3Y89.1%
EBIT Next 5Y68.49%
FCF growth 1Y187.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y801.58%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
What is the valuation status for TMDX stock?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for TMDX stock?
The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 47.25 and the Price/Book (PB) ratio is 11.2.
What is the financial health of TRANSMEDICS GROUP INC (TMDX) stock?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.